Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled liposomal ciprofloxacin in adults with non-cystic fibrosis bronchiectasis and Pseudomonas aeruginosa infection
2008-000264-17Phase 2Completed
- Sponsor
- Paradigm Biopharmaceuticals
- Start
- Feb 2008
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of liposomal ciprofloxacin hydrochloride in bronchiectasis and Pseudomonal infection (2 arms), sponsored by Paradigm Biopharmaceuticals. Primary endpoints: Mean change in log10 CFU of Pseudomonas aeruginosa per gram sputum from baseline to end of treatment and Safety and tolerability. Started Feb 2008; status: completed.
02
Drugs
liposomal ciprofloxacin hydrochloride
03
Conditions
bronchiectasisPseudomonal infection
Beyond the preview
Go deeper on 2008-000264-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000264-17.